FindTrial
Sign In

The safety and efficacy of plasma-derived factor VIII concentrate produced by National Blood Center, Thai Red Cross Society

The safety and efficacy of plasma-derived factor VIII concentrate produced by National Blood Center, Thai Red Cross Society

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170228002
Enrollment
Unknown
Registered
2017-02-28
Start date
2017-03-13
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia patients with factor VIII clotting activity less than five percent activity and no antibody. Hemophilia A&#44

Interventions

Subject with patient&#44
age equal to or more than ten years of age.
No Intervention Drug
Factor VIII concentrate

Sponsors

Thai Hematology Society
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
10 Years to 60 Years

Inclusion criteria

Inclusion criteria: Hemophilia A patient, age equal to or more than ten years of age.

Exclusion criteria

Exclusion criteria: Hemophilia A patients with inhibitor.

Design outcomes

Primary

MeasureTime frame
Incremental level of factor VIII clotting activity at 30 minutes Percent/1 unit of factor VIII concentrate/kg,Half life of infused factor VIII concentrate at 30 minutes, 4 hours and 24 hours Hour—

Secondary

MeasureTime frame
Inhibitor at 3 months Bethesda unit,Infectious markers at 3 months Positive test—

Countries

Thailand

Contacts

Public ContactAmpaiwan Chuansumrit

Faculty of Medicine Ramathibodi Hospital, Mahidol University

ampaiwan.jua@mahidol.ac.th0818338494

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026